{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:10:37Z","timestamp":1771647037893,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00292-021-01019-3","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T11:02:36Z","timestamp":1636455756000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aktualisierte WHO-Klassifikation der Tumoren der Mamma","Updated WHO classification of tumors of the breast"],"prefix":"10.1007","volume":"42","author":[{"given":"Annette","family":"Lebeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison\u00a0KH, Hammond\u00a0MEH, Dowsett\u00a0M et\u00a0al (2020) Estrogen and Progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J\u00a0Clin Oncol 38:1346\u20131366","journal-title":"J Clin Oncol"},{"key":"1019_CR2","unstructured":"Deutsche Krebsgesellschaft, Deutsche Gesellschaft F\u00fcr Gyn\u00e4kologie und Geburtshilfe (2020) S3-Leitlinie \u201eFr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms\u201c. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Mammakarzinom_4_0\/Version_4.4\/LL_Mammakarzinom_Langversion_4.4.pdf. Zugegriffen: 26. Sept. 2021"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston\u00a0CW, Ellis\u00a0IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a\u00a0large study with long-term follow-up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"key":"1019_CR4","volume-title":"WHO classification of tumours of the breast","author":"SR Lakhani","year":"2012","unstructured":"Lakhani\u00a0SR, Ellis\u00a0I, Schnitt\u00a0S et\u00a0al (2012) WHO classification of tumours of the breast. IARC Press, Lyon"},{"key":"1019_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00292-021-00934-9","volume":"42","author":"A Lebeau","year":"2021","unstructured":"Lebeau\u00a0A, Denkert\u00a0C (2021) Aktualisierte WHO-Klassifikation der Tumoren der Mamma: Die wichtigsten \u00c4nderungen. Pathologe 42:270\u2013280","journal-title":"Pathologe"},{"key":"1019_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00292-019-0578-3","volume":"40","author":"A Lebeau","year":"2019","unstructured":"Lebeau\u00a0A, Denkert\u00a0C, Sinn\u00a0P et\u00a0al (2019) Update of the German S3 breast cancer guideline : what is new for pathologists? Pathologe 40:185\u2013198","journal-title":"Pathologe"},{"issue":"7","key":"1019_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen\u00a0TO, Leung\u00a0SCY, Rimm\u00a0DL et\u00a0al (2021) Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J\u00a0Natl Cancer Inst 113(7):808\u2013819","journal-title":"J Natl Cancer Inst"},{"key":"1019_CR8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi\u00a0G, Klimstra\u00a0DS, Abedi-Ardekani\u00a0B et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31:1770\u20131786","journal-title":"Mod Pathol"},{"key":"1019_CR9","doi-asserted-by":"publisher","first-page":"151481","DOI":"10.1016\/j.anndiagpath.2020.151481","volume":"45","author":"SJ Schnitt","year":"2020","unstructured":"Schnitt\u00a0SJ, Brogi\u00a0E, Chen\u00a0YY et\u00a0al (2020) American registry of pathology expert opinions: the spectrum of lobular carcinoma in situ: diagnostic features and clinical implications. Ann Diagn Pathol 45:151481","journal-title":"Ann Diagn Pathol"},{"key":"1019_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/jclinpath-2012-200733","volume":"65","author":"RA Walker","year":"2012","unstructured":"Walker\u00a0RA, Hanby\u00a0A, Pinder\u00a0SE et\u00a0al (2012) Current issues in diagnostic breast pathology. J\u00a0Clin Pathol 65:771\u2013785","journal-title":"J Clin Pathol"},{"key":"1019_CR11","volume-title":"WHO classification of tumours\u2014breast tumours","author":"Who Classification of Tumours Editorial Board","year":"2019","unstructured":"Who Classification of Tumours Editorial Board (2019) WHO classification of tumours\u2014breast tumours. International Agency for Research on Cancer, Lyon"},{"key":"1019_CR12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2014.59.7559","volume":"33","author":"AC Wolff","year":"2015","unstructured":"Wolff\u00a0AC, Hammond\u00a0ME, Hicks\u00a0DG et\u00a0al (2015) Reply to E.A. Rakha et\u00a0al. J\u00a0Clin Oncol 33:1302\u20131304","journal-title":"J Clin Oncol"},{"key":"1019_CR13","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff\u00a0AC, Hammond\u00a0ME, Hicks\u00a0DG et\u00a0al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J\u00a0Clin Oncol 31:3997\u20134013","journal-title":"J Clin Oncol"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff\u00a0AC, Hammond\u00a0MEH, Allison\u00a0KH et\u00a0al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J\u00a0Clin Oncol 36:2105\u20132122","journal-title":"J Clin Oncol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-021-01019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-021-01019-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-021-01019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T22:17:00Z","timestamp":1645222620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-021-01019-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":14,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s00292-021-01019-3","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"5 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Lebeau \u00fcbte f\u00fcr die Firmen Roche Pharma, AstraZeneca, Novartis und MSD Sharp&Dhome eine Vortragst\u00e4tigkeit sowie f\u00fcr die Firmen Roche Pharma, Novartis, Diaceutics, Daiichi Sankyo und MSD Sharp&Dhome eine Beratert\u00e4tigkeit aus. Sie erhielt von der Firma Roche Pharma AG Studienunterst\u00fctzung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}